What question did this study address?
The manuscript describes the pharmacokinetics of tizoxanide, the active
metabolite of nitazoxanide using a physiologically based pharmacokinetic
(PBPK) model. The validated PBPK model was used to estimate the optimal
doses required for SARS-CoV-2 treatment or prevention such that
>90% of the simulated population would have tizoxanide
concentrations in the plasma and lung above the reported 90% effective
concentration (EC90) value of nitazoxanide for the
entire dosing interval.